公平贸易委员会指控Big 3PBM公司提高药品价格,伤害小药店,阻碍低成本选择,引发有计划的诉讼。 FTC accuses Big 3 PBMs of raising drug prices, harming small pharmacies, and obstructing low-cost options, prompting a planned lawsuit.

联邦贸易委员会(FTC)指控美国药剂福利管理者(PBMS)抬高药品价格,伤害小药店,破坏非专利药和生物类的低成本选择。 The Federal Trade Commission (FTC) accuses Pharmacy Benefit Managers (PBMs) in the US of driving up drug prices, harming small pharmacies, and undermining low-cost options like generics and biosimilars. 美国联邦贸易委员会确定"三大"PBM - - CVS Caremark,Optum Rx和Express Scripts - - 具有特别有害的做法. The FTC identified the "Big 3" PBMs - CVS Caremark, Optum Rx, and Express Scripts - as having particularly harmful practices. 批评者声称联邦贸易委员会的报告缺乏对患者有害的证据, 但联邦贸易委员会表示这是由于PBM不愿提供必要的文件. Critics claim the FTC's report lacks evidence of patient harm, but the FTC states this is due to the PBMs' reluctance to provide necessary documentation. 随后,公平贸易委员会透露,计划对大3PBM公司使用胰岛素和其他药物的退款提出诉讼。 Subsequently, the FTC revealed plans to file a lawsuit against the Big 3 PBMs over their use of rebates for insulin and other drugs.